Drugs Containing Excipient (Inactive Ingredient) SODIUM ACETATE ANHYDROUS

Branded drugs containing SODIUM ACETATE ANHYDROUS excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Eli Lilly and Company	FORTEO	teriparatide	0002-8400	SODIUM ACETATE ANHYDROUS
Lantheus Medical Imaging Inc	DEFINITY RT	perflutren	11994-017	SODIUM ACETATE ANHYDROUS	2037-05-04
Noven Therapeutics LLC	SECUADO	asenapine	68968-0172	SODIUM ACETATE ANHYDROUS	2033-09-22

Generic drugs containing SODIUM ACETATE ANHYDROUS excipient

Company	Ingredient	NDC	Excipient
Eli Lilly and Company	teriparatide	0002-8400	SODIUM ACETATE ANHYDROUS
Walgreen Company	cetirizine hydrochloride	0363-2088	SODIUM ACETATE ANHYDROUS
Walgreen Company	cetirizine hydrochloride	0363-2102	SODIUM ACETATE ANHYDROUS
WALGREEN COMPANY	cetirizine hydrochloride	0363-2106	SODIUM ACETATE ANHYDROUS
Mylan Pharmaceuticals Inc	difluprednate	0378-7518	SODIUM ACETATE ANHYDROUS
Henry Schein Inc	esmolol hydrochloride	0404-9785	SODIUM ACETATE ANHYDROUS

# Sodium Acetate Anhydrous Excipient Market: Dynamics, Supply Chain, Pricing, and Financial Trajectory

Last updated: August 2, 2026

Sodium acetate anhydrous is a low-cost pharmaceutical excipient and processing material used primarily as a buffering agent, pH adjuster, electrolyte, and formulation aid. Its market is driven by injectable products, biologics manufacturing, oral and topical formulations, laboratory demand, and industrial applications rather than by standalone pharmaceutical revenue. The product has limited patent protection, low switching costs, and strong exposure to acetic acid, sodium hydroxide, energy, packaging, regulatory, and quality-system costs.

Public companies generally do not report sodium acetate anhydrous revenue separately. The financial outlook is therefore best assessed through volume growth, specification premiums, supply concentration, manufacturing qualification costs, and raw-material pricing rather than through a directly reported market capitalization or product-level revenue forecast.

What is sodium acetate anhydrous and how is it used in pharmaceuticals?

Sodium acetate anhydrous is the water-free sodium salt of acetic acid. Its principal chemical identifiers are:

Attribute	Data
Chemical name	Sodium acetate anhydrous
Formula	C2H3NaO2
Molecular weight	82.03 g/mol
CAS number	127-09-3
Appearance	White crystalline powder or granules
Primary pharmaceutical role	Buffering agent, pH adjuster, electrolyte, formulation aid
Hydrated counterpart	Sodium acetate trihydrate
Common compendial references	USP-NF, Ph. Eur., BP and other national pharmacopoeias

In pharmaceutical formulations, sodium acetate can control pH and contribute sodium ions to a formulation. It is relevant to parenteral products because buffer selection affects stability, degradation, solubility, osmolality, container compatibility, and tolerability.

The anhydrous grade is distinct from sodium acetate trihydrate. The two forms have different molecular weights, water content, assay calculations, storage behavior, and formulation equivalence. A manufacturer cannot substitute one grade without recalculating the formulation and confirming stability and process performance.

What pharmaceutical products use sodium acetate anhydrous?

Sodium acetate is used across several dosage-form categories, although commercial use varies by product and region.

Injectable and parenteral formulations

Injectable applications are commercially important because pharmaceutical-grade sodium acetate must meet tighter requirements for identity, purity, bioburden control, endotoxin risk management, elemental impurities, and manufacturing traceability.

Potential uses include:

• Buffer systems for injectable drug products
• Electrolyte replacement formulations
• Parenteral nutrition products
• Diluent and reconstitution systems
• Biologic and vaccine manufacturing buffers
• Cell-culture and downstream purification solutions

The injectable segment creates higher supplier qualification barriers than technical or food-grade demand. A change in source can require comparative testing, stability work, change-control documentation, and regulatory assessment.

Oral, topical, and laboratory formulations

Sodium acetate can also be used in oral and topical products as a buffering or pH-control ingredient. Laboratory and bioprocessing demand includes preparation of buffers, chromatography solutions, cell-culture media, and analytical reagents.

Pharmaceutical demand is therefore fragmented. A single finished product rarely consumes large quantities, but recurring demand across many formulations can support a stable base market.

How large is the sodium acetate anhydrous market?

No authoritative public source identifies a globally reported market size exclusively for pharmaceutical-grade sodium acetate anhydrous. Commercial market reports commonly combine sodium acetate with hydrated sodium acetate, food-grade material, industrial grades, laboratory reagents, and specialty chemicals. Those broader estimates should not be treated as pharmaceutical-excipient revenue.

The addressable market has three layers:

Market layer	Demand characteristics	Margin profile
Industrial sodium acetate	High volume, price sensitive, limited qualification	Low
Food and laboratory grade	Moderate specification requirements and fragmented buyers	Low to medium
Pharmaceutical and injectable grade	Lower volume, high documentation and qualification burden	Medium to high

The pharmaceutical portion is likely small relative to total sodium acetate consumption, but it has greater value per kilogram because of testing, documentation, packaging, quality assurance, and validated manufacturing requirements.

A realistic financial model should separate:

1. Chemical production revenue.
2. Pharmaceutical-grade conversion and testing revenue.
3. Distribution and repackaging revenue.
4. Bioprocess and custom-buffer revenue.
5. Freight, compliance, and quality-service costs.

What factors are driving sodium acetate anhydrous demand?

Growth in injectable drugs and biologics

Demand for pharmaceutical excipients used in injectable products benefits from growth in biologics, specialty injectables, parenteral nutrition, and hospital-administered therapies. Sodium acetate is not a high-value biologic excipient, but it can participate in the broader expansion of sterile manufacturing and buffer preparation.

Biologics manufacturing can generate recurring demand for controlled-purity raw materials. The strongest opportunities are usually in validated supply programs rather than spot sales.

Expansion of contract development and manufacturing

CDMOs and contract manufacturers purchase excipients for development batches, clinical supply, commercial production, and process-scale activities. Their procurement standards can favor suppliers with:

• Multisite manufacturing capability
• Long-term quality agreements
• Electronic documentation
• Change-notification controls
• Pharmacopoeial compliance
• Audit readiness
• Lot-to-lot consistency

CDMO demand can improve supplier retention, but it can also increase price pressure through centralized procurement.

Regional manufacturing and supply-chain resilience

Pharmaceutical manufacturers have increased scrutiny of critical raw materials, including excipients used in sterile products. Sodium acetate is generally not viewed as a uniquely scarce material, but supply interruptions can affect batch release when a qualified alternate source is unavailable.

Regional inventory, dual sourcing, and validated alternate suppliers can create commercial value even when the chemical itself is widely available.

Food, heating, laboratory, and industrial demand

Sodium acetate has nonpharmaceutical uses in food preservation, textile processing, concrete-related applications, heating packs, wastewater treatment, and laboratory chemistry. These sectors influence capacity utilization and raw-material economics but generally offer lower margins than pharmaceutical-grade sales.

How is sodium acetate anhydrous manufactured?

Commercial production generally involves neutralizing acetic acid with a sodium base, followed by concentration, crystallization, drying, milling, and packaging. Sodium hydroxide or another sodium source can be used depending on the process.

The principal cost inputs are:

• Glacial acetic acid
• Sodium hydroxide or sodium carbonate
• Electricity and thermal energy
• Water and wastewater treatment
• Drying and crystallization
• Testing and quality assurance
• Pharmaceutical packaging
• Freight and inventory financing

The chemistry is mature and does not create a major technological barrier. The economic barriers arise from quality systems, plant qualification, contamination control, documentation, and customer approval.

What manufacturing barriers affect pharmaceutical supply?

For pharmaceutical-grade material, suppliers must control:

• Assay and related impurities
• Water content
• Residual solvents, where applicable
• Chloride, sulfate, heavy metals, and elemental impurities
• Microbial quality
• Endotoxin risk for relevant applications
• Particle size and flow properties
• Packaging integrity
• Traceability and batch release

The required specification depends on the finished-product use and the applicable monograph. A supplier producing industrial sodium acetate cannot automatically sell material into a regulated injectable application.

How does sodium acetate anhydrous pricing work?

Pricing is usually negotiated by grade, volume, packaging, delivery region, and documentation requirements. Public spot-price transparency is limited because pharmaceutical sales are commonly conducted through direct contracts and distributors.

Typical pricing variables include:

Variable	Commercial effect
USP-NF or Ph. Eur. compliance	Increases testing and documentation cost
Sterile or low-bioburden handling	Can materially increase price
Small-batch packaging	Raises conversion and logistics cost
Annual volume commitment	Usually lowers unit price
Dual compendial certification	Raises testing and release requirements
Supplier qualification	Creates switching costs
Regional inventory	Adds warehousing cost but improves service
Raw-material volatility	Changes contract pricing or surcharge terms

Commodity-grade sodium acetate can be sold on a price-per-kilogram basis. Pharmaceutical-grade material is more often priced as a combination of product, qualification, documentation, packaging, and supply assurance.

What is the financial trajectory for sodium acetate anhydrous?

The expected financial trajectory is stable to moderately positive in pharmaceutical applications, with limited potential for explosive growth. Revenue expansion is more likely to come from volume growth, grade upgrades, and customer retention than from large price increases.

Base-case trajectory

The base case includes:

• Low-single-digit volume growth in pharmaceutical applications
• Stable demand from established injectable and oral products
• Periodic price increases tied to labor, energy, testing, and logistics
• Continued competition among chemical and excipient suppliers
• Limited patent-driven margin expansion

Upside case

The upside case depends on:

• Greater biologics and injectable production
• Increased outsourcing to CDMOs
• More regionalized pharmaceutical supply chains
• Qualification of additional pharmaceutical-grade capacity
• Higher demand for documented, compendial, low-bioburden material
• Supplier consolidation that improves pricing power

Downside case

The downside case includes:

• Raw-material cost deflation
• Substitution by alternative buffers
• Formulation redesign that removes sodium acetate
• Excess chemical capacity
• Customer movement toward lower-cost suppliers
• Reduced demand for specific injectable products
• Regulatory findings that disqualify a manufacturing site

The product’s low unit cost limits absolute revenue exposure for most finished-drug manufacturers. Its strategic value is higher in products where a supplier change could trigger validation work or delay batch release.

What patents protect sodium acetate anhydrous?

Sodium acetate anhydrous itself has no meaningful composition-of-matter patent barrier. It is an established inorganic-organic salt with long-standing commercial and pharmaceutical use.

Relevant intellectual-property protection is more likely to involve:

• A finished drug formulation
• A specific buffer system
• A biologic manufacturing process
• A lyophilized composition
• A controlled pH or osmolality range
• A delivery device
• A method of stabilizing an active ingredient

Those rights generally protect the drug product or manufacturing process, not sodium acetate as a standalone excipient.

What formulation patents can include sodium acetate?

A formulation patent may claim sodium acetate as one component of a broader composition. The enforceable value depends on claim scope, concentration ranges, pH limits, active ingredient identity, excipient combinations, and manufacturing steps.

A supplier selling sodium acetate normally does not infringe such claims merely by manufacturing the excipient. Risk can arise if the supplier sells a proprietary premixed buffer or participates in a claimed drug-manufacturing process.

What is the FDA regulatory status of sodium acetate anhydrous?

Sodium acetate is recognized as a pharmaceutical excipient and is listed in the FDA Inactive Ingredient Database for relevant drug products and routes of administration. The database is product- and route-specific and does not constitute blanket approval for every concentration, dosage form, or injectable use.[1]

For a new drug application or abbreviated new drug application, the sponsor must show that the proposed excipient use is appropriate for the product. Key considerations include:

• Grade and compendial status
• Route of administration
• Maximum daily exposure
• Concentration
• Sodium contribution
• pH and osmolality
• Impurity profile
• Supplier qualification
• Manufacturing controls

Sodium acetate is not an active pharmaceutical ingredient requiring its own FDA approval. Its regulatory significance arises from the finished product and the proposed conditions of use.

What is the Orange Book status of sodium acetate anhydrous?

Sodium acetate anhydrous does not have an independent Orange Book listing because the Orange Book lists approved drug products and associated patents or exclusivity, not ordinary excipients as standalone products.[2]

An Orange Book-listed finished product may contain sodium acetate. Any patent or exclusivity protecting that product would generally relate to the active ingredient, formulation, method of use, or other product attributes.

When does sodium acetate anhydrous lose exclusivity?

Sodium acetate anhydrous has no practical standalone pharmaceutical exclusivity timeline. It is a mature excipient available from multiple chemical and excipient suppliers.

Finished drugs containing sodium acetate can have exclusivity periods under the Hatch-Waxman framework, but those periods attach to the approved drug product rather than to the excipient. A generic applicant may submit a Paragraph IV certification against Orange Book-listed patents for the finished drug if relevant, but sodium acetate itself does not create a Paragraph IV barrier.[3]

Which companies supply pharmaceutical-grade sodium acetate?

The commercial supply base includes large chemical manufacturers, pharmaceutical-excipient suppliers, laboratory reagent companies, and regional distributors. Product availability varies by geography and grade.

Potential supplier categories include:

• Global excipient manufacturers
• Large chemical companies with compendial product lines
• Laboratory reagent suppliers
• Regional pharmaceutical raw-material distributors
• Custom buffer and bioprocess suppliers

Supplier selection should focus on the exact grade, site of manufacture, compendial claims, packaging configuration, audit history, change-control terms, and regulatory support. A catalog listing alone does not establish suitability for an injectable product.

How strong is the patent estate for sodium acetate anhydrous?

The standalone patent estate is weak because the material is old, generic, and widely manufactured. Commercial defensibility depends on operational factors:

Defensibility factor	Assessment
Composition patent	Very weak or absent
Process patent	Limited relevance for standard production
Regulatory qualification	Moderate
Customer switching costs	Moderate in injectable applications
Manufacturing scale	Important
Quality documentation	Important
Supply continuity	Important
Brand and distributor access	Moderate
Proprietary formulation value	Possible only in downstream products

The strongest competitive position belongs to suppliers that combine reliable production with pharmaceutical documentation and customer qualification. Patent ownership is not the main source of value.

What generic entry risks exist for drugs containing sodium acetate?

Generic entry risk is determined by the active pharmaceutical ingredient, dosage form, therapeutic market, and Orange Book patent position. Sodium acetate generally has little effect on generic entry risk.

For a drug containing sodium acetate, the relevant risks are:

• Whether the excipient is required for product performance
• Whether the generic can use a different buffer
• Whether formulation patents claim sodium acetate specifically
• Whether the reference product has injectable complexity
• Whether the supplier is qualified for the generic manufacturer
• Whether manufacturing changes affect bioequivalence or stability

Injectable products may face higher technical development barriers than immediate-release oral products, but those barriers arise from sterility, container closure, stability, and manufacturing requirements.

What licensing deals and settlement agreements affect sodium acetate anhydrous?

No major licensing or patent-settlement framework is associated with sodium acetate anhydrous as a standalone excipient. Licensing and settlements may affect finished products that use sodium acetate, especially products with formulation, biologic-process, or delivery patents.

A commercial agreement involving sodium acetate is more likely to be:

• A supply agreement
• A quality agreement
• A distribution arrangement
• A contract manufacturing agreement
• A technology-transfer agreement
• A proprietary premixed-buffer agreement

These agreements are generally private and are not reported as sodium acetate-specific licensing transactions.

What is the competitive landscape versus other pharmaceutical buffers?

Sodium acetate competes with sodium citrate, citric acid, phosphate buffers, histidine, tromethamine, bicarbonate systems, and other formulation-specific buffers.

Buffer	Relative commercial position	Key consideration
Sodium acetate	Established, low-cost	Adds sodium and acetate ions
Sodium citrate	Widely used	Strong chelation and pH-control properties
Phosphate	Common	Can affect precipitation and ionic strength
Histidine	Important in biologics	Higher value and formulation specificity
Tromethamine	Used in selected products	Different buffering range and safety profile
Bicarbonate	Relevant in selected parenteral uses	Stability and handling constraints

Sodium acetate’s advantages are cost, availability, established chemistry, and broad supplier access. Its limitations include sodium loading, formulation-specific pH range, ionic-strength effects, and possible incompatibility with certain active ingredients or excipient systems.

Key Takeaways

• Sodium acetate anhydrous is a mature, low-cost pharmaceutical excipient with limited standalone patent protection.
• Its main roles are buffering, pH adjustment, electrolyte contribution, and bioprocessing support.
• Pharmaceutical-grade revenue is not publicly reported separately from broader sodium acetate or excipient sales.
• Injectable, biologic, parenteral nutrition, CDMO, and bioprocessing demand provide the strongest growth drivers.
• Financial growth is likely to be steady rather than high-growth, with margins supported by qualification, documentation, packaging, and supply reliability.
• Raw-material exposure is concentrated in acetic acid, sodium hydroxide, energy, testing, and logistics.
• FDA status depends on the route, dosage form, concentration, and specific inactive-ingredient precedent in the finished product.
• Sodium acetate has no independent Orange Book exclusivity or Paragraph IV position.
• Competitive advantage comes from validated quality systems and reliable supply, not composition patents.
• Finished-drug patents may claim formulations containing sodium acetate, but those rights protect the drug product or process.

FAQs

Is sodium acetate anhydrous interchangeable with sodium acetate trihydrate?

No. The forms have different molecular weights and water content. Substitution requires formulation recalculation, analytical confirmation, and stability assessment.

Does sodium acetate anhydrous require a drug master file?

A drug master file may be used by a supplier to provide confidential manufacturing and quality information to regulators, but the need depends on the customer’s regulatory strategy, jurisdiction, grade, and product application.

Is sodium acetate anhydrous suitable for injectable drugs?

It can be suitable when the specific grade meets applicable compendial, purity, microbiological, endotoxin, packaging, and manufacturing requirements. Suitability is product- and route-specific.

Can a generic manufacturer change the sodium acetate supplier?

Usually, but the change may require supplier qualification, comparative testing, stability data, regulatory notification, or approval depending on the product, jurisdiction, and material specification.

Does sodium acetate anhydrous have biosimilar patent risk?

The excipient itself does not create biosimilar patent risk. Risk arises from patents covering the biologic, formulation, manufacturing process, delivery system, or method of treatment.

References

1. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
3. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application submissions: Refuse-to-receive standards. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/abbreviated-new-drug-application-anda-submissions